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Abstract  40 
Around 1500 active pharmaceutical ingredients are currently in use, however the environmental 41 
occurrence and impacts of only a small proportion of these has been investigated. Recognising that it 42 
would be impractical to monitor and assess all pharmaceuticals that are in use, a number of previous 43 
studies have proposed the use of prioritisation approaches to identify substances of most concern so 44 
that resources can be focused on these. All of these previous approaches suffer from limitations. 45 
Here, we draw on experience from previous prioritisation exercisea and present a holistic approach 46 
for prioritising pharmaceuticals in the environment in terms of risks to aquatic and soil organisms, 47 
avian and mammalian wildlife and humans. The approach considers both apical ecotoxicological 48 
endpoints as well as potential non-apical effects related to the therapeutic mode of action. Application 49 
of the approach is illustrated for 146 active pharmaceuticals that are either used in the community or 50 
in hospital settings in the United Kingdom. Using the approach sixteen compounds were identified as 51 
a potential priority. These substances include compounds belonging to the antibiotic, antidepressant, 52 
anti-inflammatory, antidiabetic, antiobesity and estrogen classes as well as associated metabolites. 53 
We recommend that in the future, the prioritisation approach be applied more broadly around the 54 
different regions of the World. 55 
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Introduction 65 
Active pharmaceutical ingredients (APIs) have been widely detected in the natural environment 66 
across the world [1-3]. As they are biologically active compounds, designed to interact with specific 67 
pathways/processes in target humans and animals, concerns have been raised over the potential side 68 
effects of these substances in the environment and, over the past 15 years, a substantial amount of 69 
work has been done on the occurrence, fate, effects and risks of pharmaceuticals in the natural 70 
environment. There have also been regulatory developments around the monitoring of 71 
pharmaceuticals in the environment. For example, seven pharmaceuticals/hormones have been 72 
placed on the watch list under the European Environmental Quality Standards Directive [4] and Water 73 
Framework Directive [5] and it is possible that, in the future, these compounds will be included in 74 
European statutory monitoring programmes. 75 
While a large amount of data has been published in the past decade on different aspects of APIs in 76 
the environment, information is still only available for a small proportion of the 1500 or so active 77 
pharmaceutical ingredients that are currently in use. It is possible, therefore, that monitoring and 78 
effects-based studies are missing substances that could be causing adverse impacts in the 79 
environment. It would be impossible to experimentally assess the hazards and risks for all the 80 
pharmaceuticals in use in a timely manner. One solution to this problem is to employ formal 81 
prioritisation approaches to identity those compounds that are likely to pose the greatest risk in a 82 
particular situation and, therefore, which need further attention. A number of prioritisation methods 83 
have already been proposed, and applied to, human and veterinary APIs [6-10]. Prioritisation 84 
approaches are also available for other classes of emerging contaminant such as pesticide 85 
metabolites [11]. Many of these approaches use exposure and toxicological predictions or information 86 
on API potency in humans so they can be readily applied to large numbers of compounds. Until now, 87 
prioritisation methods for APIs have tended to focus on risks of parent compounds in surface waters 88 
to aquatic organisms and risks to humans via drinking water consumption and tended to focus on 89 
single use categories (e.g. prescription or hospital use). Less emphasis has been placed on risks to 90 
other environmental compartments such as soils, sediments and ground waters, risks to top predators 91 
or on the risks of metabolites of APIs. 92 
In the present study, we describe a holistic risk-based prioritisation approach for identifying APIs of 93 
concern in aquatic and terrestrial systems. The use of the prioritisation approach is illustrated using a 94 
subset of APIs used in primary and secondary care in the United Kingdom as well as those distributed 95 
by pharmacists ‘over the counter’ and major metabolites of these. The approach considers aquatic 96 
and terrestrial exposure routes and acute and chronic effects on algae, invertebrates, fish, birds and 97 
mammals, including humans. Effects relating to the therapeutic mode of action are also considered. 98 
The approach is illustrated using 146 active ingredients that were either high usage in the UK or 99 
where experts indicated that they might be of environmental concern. While the approach has been 100 
applied to the UK situation, there is no reason why it cannot be applied to prioritise APIs in use in 101 
other regions of the World. 102 
Methods  103 
The prioritisation approach used risk scores (RS) as the primary parameter to rank the APIs in terms 104 
of their potential environmental risk (Figure 1 A, B). Risk score values were calculated by comparing 105 
predictions of exposure of APIs in different environmental compartments to measures of potential 106 
hazard towards different organisms from different trophic levels. The prioritisation process considered 107 
aquatic and terrestrial organisms as well as humans, acute and chronic apical ecotoxicological effects 108 
and potential effects related to the mode of action of an API (Figure 1 A, B). In the next sections we 109 
describe how the exposure concentrations and hazard paramaters were derived. Specific equations 110 
are provided in the Supplemental Data. 111 
Identification of substances for prioritisation 112 
In the United Kingdom (UK), the main ways that pharmaceuticals are made available to patients are 113 
through the fulfilment of primary care prescriptions by pharmacies and dispensing in secondary care 114 
(including hospitals). Some can also be purchased ‘over-the-counter’ at retail outlets. It would be a 115 
mammoth task to determine the usage of all compounds in the UK. We therefore, developed a 116 
substance list for prioritisation that included the top usage compounds in these different categories. 117 
To ensure that the list caught compounds of low use but very high potency, we also used expert 118 
opinion to identify potent compounds that might be of concern. Forty international experts from 119 
academia, industry and Government agencies based in North America, Europe and Asia were 120 
contacted via email. These experts were selected based on their track record in the area of 121 
ecotoxicology and environmental risks of pharmaceuticals. Many of them had participated in the 122 
Society of Environmental Toxicology and Chemistry ‘Big Questions’ exercise on pharmaceuticals and 123 
personal care products in the environment [12]. Their responses were used to collate a list of 124 
substances of high perceived concern. 125 
Annual pharmaceutical usage data for the top most prescribed pharmaceuticals in primary care (by 126 
active ingredient mass) in the UK were collated from Prescription Cost Analysis (PCA) data available 127 
for England [13], Scotland [14] and Wales [15]. The available PCA data obtained from Northern 128 
Ireland was not sufficient to calculate pharmaceutical usage. To reduce the time required to collate 129 
the data, the usage of all pharmaceuticals present on the PCA data for Wales was calculated 130 
(approximately 1000 active ingredients). Usage data were then obtained for England and Scotland for 131 
the top 300 compounds in use in Wales. These data were then used to generate a list of the top 100 132 
pharmaceuticals by mass for Great Britain. Twelve substances with high usage but considered by the 133 
project team to fall outside the scope of this project were excluded from further prioritisation. These 134 
compounds were aliginic acid compound preparations, calcium carbonate, co-magaldrox 135 
(magnesium/aluminium hydroxide), ergocalciferol, ferrous fumarate, ferrous sulphate, glucose, lithium 136 
carbonate, omega-3 marine triglycerides, potassium chloride, sodium bicarbonate and sodium 137 
valproate.  138 
Data on pharmaceutical usage in secondary care in 2012 was provided to the project team by the 139 
British Generic Manufacturers Association (BGMA). Data were provided on the usage, by mass, of 140 
the top twenty most used pharmaceuticals in secondary care. Three compounds (paracetamol, 141 
amoxicillin and codeine) that were also present on the primary usage lists had their primary and 142 
secondary care usage combined. The identity of pharmaceutical active ingredients present in 143 
pharmaceutical products available over-the-counter were obtained from information available on 144 
online retailer websites (e.g. the Boots Company website) 145 
As some compounds will be extensively metabolised in the body, for these substances, the 146 
environment will be exposed to the metabolite and not the parent compound. Data were therefore 147 
also obtained on the extent of metabolism of the high use compounds and on the identity of the major 148 
metabolites. The recent Chemical Investigation Program (CIP) in the UK has monitored 12 149 
pharmaceuticals in wastewater treatment plant (WWTP) effluent [16]. Compounds monitored in CIP 150 
but which were not in the top usage compound list or which were not identified by the experts were 151 
also added to the list for prioritisation. Overall, 146 compounds were identified for further quantitative 152 
prioritisation. An additional 23 compounds were identified that are available over-the-counter which 153 
were ranked using a more simple chemical classification approach due to the absence of quantitative 154 
usage data. 155 
Environmental exposure estimation  156 
Predicted environmental concentrations of selected pharmaceuticals in surface waters (PECsw) and 157 
terrestrial systems (PECsoil) were estimated using standard algorithms that are described in existing 158 
regulatory guidance documents (Supplemental Data, Equations 1-7) [17, 18]. The algorithms assume 159 
that pharmaceutical usage by the population is distributed evenly both temporally and spatially. The 160 
property data for APIs, collated to aid the determination of environmental exposure, included the acid 161 
dissociation constant (pKa); octanol-water partition coefficient (Kow); solid-water distribution coefficient 162 
(Kd) and organic carbon partition coefficient (Koc).  These data were collated from a number of sources 163 
including the peer-reviewed literature, grey literature and available online databases (e.g. drugbank 164 
[19]). Where experimentally determined data were unavailable, estimation tools, such as Quantitative 165 
Structure-Property Relationships [17, 20, 21] were used to fill the data gaps. For example, Koc was 166 
predicted using an estimation model developed for ionisable organic chemicals (Supplemental Data, 167 
Equations 8-11). Default values of pH of soil recommended by the model developers [20] were used 168 
in the Koc estimation (i.e. 5.8 for acids and pH 4.5 for bases).  169 
The fish steady state plasma concentration (FssPC) resulting from exposure via surface water was 170 
predicted based on estimates of the partitioning of an API between the aqueous phase and arterial 171 
blood in the fish (Pblood :water) [22]. This partition coefficient was initially estimated based on the Log Kow 172 
of the API, and this was subsequently combined with the PECsw to estimate the FssPC (Supplemental 173 
Data, Equations 12-15).  174 
To estimate concentrations in fish, the Bioconcentration factor for fish (BCFfish) was estimated 175 
according to the approach of Fu et al. [23] assuming a pH of surface water of 7.0. The predicted 176 
environmental concentration in fish as food (PECfish) was then calculated from the BCF and the 177 
predicted surface water concentration (Supplemental Data, Equations 16-20). To estimate the 178 
concentration of an API in earthworms (PECearthworm), the concentration in the earthworms on a wet 179 
weight basis (Cearthworm) was calculated using an estimate of the concentration in porewater (Cporewater) 180 
and the BCF for earthworms calculated according to the approach in the Technical guideline 181 
Document (TGD; Supplemental Data, Equations 21-23)  [17]. 182 
Hazard characterisation  183 
Predicted no effect concentrations (PNEC) of pharmaceuticals were derived based on either 184 
experimental or estimated ecotoxicity data, using appropriate safety factors from the Technical 185 
Guideline Document (TGD) [17] (Supplemental Data, Equations 24). Where multiple ecotoxicological 186 
values were available, the most sensitive end-point was used for the generation of the PNEC.  187 
Chronic and acute aquatic and terrestrial ecotoxicity data for standard test taxa (e.g. earthworm, 188 
green algae, daphnia and fish), together with non-standard taxa and end-points, were collated for the 189 
146 pharmaceuticals (and relevant metabolites) under consideration (e.g. from the Fass [24] and 190 
ECOTOX [25] databases). A number of the compounds under consideration had no available 191 
experimentally derived ecotoxicological aquatic data. Therefore, for these compounds estimation 192 
techniques were used to fill the data gaps. A read-across approach using the OECD QSAR Toolbox 193 
was used for pharmaceuticals, and the estimation approach of Escher et al. [26] was used for 194 
metabolites. The database present in the OECD QSAR Toolbox was used to identify experimental 195 
data for molecules deemed ‘similar’ to each of the individual pharmaceutical with no data. Then within 196 
the software a relationship was built to allow an estimation of the ecotoxicological endpoint for the 197 
query molecule. The approach adopted for the identification of similar compounds was to combine the 198 
protein-binding profile with endpoint specific ones, as suggested by the Toolbox instruction manual 199 
[27]. The main procedures in the software were as follows: protein binding profile was selected as a 200 
group method to define the category. Subcategories where then established based on the 201 
classification system used by ECOSAR (US EPA). The results were then followed by a refinement for 202 
structural similarity (70 - 90% similar). The identified chemicals were then used to read across and 203 
estimate ecotoxicity data for the query pharmaceutical. Metabolite aquatic ecotoxicty data gaps were 204 
filled using the estimation approach for pharmaceutical metabolites proposed by Escher et al. [26] 205 
which uses the principle of the toxic ratio and parent ecotoxicological data to estimate the toxic range 206 
for the metabolite. For compounds with no experimentally determined earthworm ecotoxicity data, the 207 
terrestrial toxicity (14 day LC50 in mM/kg dry soil) was predicted using the Quantitative structure-208 
activity relationship (QSAR) available in ECOSAR  (US EPA; Supplemental Data, Equations 25).  209 
All human plasma therapeutic concentrations (HtPC) were obtained from published work. Limited data 210 
are available on the toxicology of APIs to birds. Therefore, acceptable daily intakes (ADI) for humans 211 
and mammalian toxicity data (rat/mouse) were collated as surrogates to determine the potential 212 
hazards of APIs for top predators (obtained from several databases e.g. MEDSAFE [28]), Drugs [29]). 213 
A PNEC for mammalian data (PNECmammal) was generated from the median lethal dose (LD50) for 214 
rat/mouse, by dividing by an assessment factor of 100. The potential hazard from drinking water was 215 
quantified by calculating the predicted no effect concentration of APIs for an adult (PNECadult) and a 216 
child (PNECchild) based on ADIs for each API using the model of Schwab et al [30] (Supplemental 217 
Data, Equations 26). 218 
Ranking scenarios 219 
To prioritise substances a risk score was calculated for the different exposure pathway/toxicity 220 
endpoint combinations by dividing the relevant exposure concentration by the relevant hazard 221 
concentration (Figure 1 A, B). For example, to calculate the risk score for subtle effects on fish the 222 
FssPC was divided by the HtPC. Compounds were then ranked based on their risk score with 223 
substances towards the top of the ranking deemed to be of most interest for that particular pathway 224 
and endpoint. 225 
Due to a lack of quantitative usage data, the over-the-counter (OTC) pharmaceuticals were classified 226 
based on their hazards to the aquatic environment using a classification system proposed by 227 
European Chemicals Agency (ECHA) [31]. Following these criterion, substances without adequate 228 
chronic toxicity data were categorised as either chronic 1, chronic 2 and chronic 3, on the basis of the 229 
lowest acute aquatic toxicity data from 96 h half maximal lethal concentration (LC50) for fish, 48 h half 230 
maximal effective concentration (EC50) for crustacean or 72/ 96 h EC50 for algae (Table 1).  231 
Results 232 
Target APIs and collation of pharmaceutical effect data  233 
Overall 146 compounds were identified for further quantitative prioritisation, these were distributed as 234 
follows:  88 were used in primary care; 20 were used in secondary care; 12 were identified as ‘high 235 
hazard’ concern, based on expert opinion; 25 major metabolites; and 4 from the previous Chemical 236 
Investigation Program (CIP1; Table 2). Twenty three compounds, sold as OTC medicines, were also 237 
identified in addition to the 146 compounds for quantitative prioritisation – these underwent a 238 
qualitative assessment. A summary of the available experimental toxicological data for 146 study 239 
compounds is provided in Table 2. Some high profile compounds had excellent multi-species/multi-240 
endpoint datasets. However, the majority of the compounds under consideration had limited 241 
ecotoxicological data available. For the standard aquatic endpoints, 82 compounds had at least one 242 
experimentally derived acute or chronic ecotoxicity endpoint available. In terms of data on mammalian 243 
safety, data were available on the toxicity of 65 compounds, 139 had an acceptable daily intake and 244 
113 had a human therapeutic plasma concentration (HtPC) (Table 2). Toxicological data were not 245 
available for any of the identified metabolites.   246 
Ranking list development 247 
The top 20 compounds derived from the different prioritisations for the aquatic and terrestrial 248 
environments are provided in Tables 3 and 4. The prioritisation based on apical acute aquatic effects 249 
at lower trophic levels indicated that amoxicillin, clarithromycin, ciprofloxacin, azithromycin and 250 
mesalazine had the highest risk scores (RS>1). For the aquatic apical chronic prioritisation process, 251 
diclofenac, atorvastatin, estradiol, mesalazine and omeprazole demonstrated the greatest risk score 252 
(RS>1). The highest ranked compounds based on apical acute effects in soil organisms were orlistat, 253 
carbamazepine and the carbamazepine metabolite, 10,11-epoxycarbamazepine (RS 1-10; Table 4). 254 
When the potential impact of subtle pharmacological effects were considered by comparing the 255 
human therapeutic concentration in plasma to estimated levels in fish, the atorvastatin metabolites 256 
ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were ranked highest (RS>10) with 257 
atorvastatin, estradiol and amitriptyline just below these substances(RS 1-10; Table 3).  258 
In the prioritisation based on potential of secondary poisoning in the aquatic environment (i.e. fish-259 
eating birds and mammals), diazepam  was ranked the highest (RS between 0.1-1), while in terrestrial 260 
environments (i.e. earthworm-eating birds and mammals) the highest ranked API was orlistat (RS 0.1-261 
1). All other pharmaceuticals had a RS <0.1 (Table 4). The risk scores of APIs prioritised according to 262 
human consumption in drinking water for all compounds were less than 1x10
-5
. The top ranked 263 
compounds were phenytoin, metformin and simvastatin (Table 3). 264 
For over-the-counter (OTC) pharmaceuticals, amorolfine, benzalkonium chloride, cetylpyridinium 265 
chloride,  dextromethorphan, dimethicone, loratadine and xylometazoline hydrochloride were 266 
assigned to category chronic 1. The category chronic 2 included cetrimide, chlorphenamine maleate, 267 
guaifenesin, hexylresorcinol and mepyramine maleate, phenylephrine and pseudoephedrine. 268 
Beclometasone dipropionate, cetirizine hydrochloride, clotrimazole, dexpanthenol, fluticasone 269 
propionate, loperamide hydrochloride and pholcodine were assigned to category chronic 3 (Table 5). 270 
Acrivastine and sodium cromoglicate were not classified as no toxicity data was available and the 271 
estimation approaches did not work for these substances. 272 
Discussion 273 
Results comparisons 274 
A final list of 16 substances including 13 parent compounds (amitriptyline, amoxicillin, atorvastatin, 275 
azithromycin, carbamazepine, ciprofloxacin, clarithromycin, diclofenac, estradiol, mesalazine, 276 
metformin, omeprazole, orlistat) and 3 metabolites (ortho-hydroxyatovastatin, para-hydroxyatovastatin 277 
and 10,11-epoxycarbamazepine) were identified that had a risk score > 1 for one or more of the risk 278 
comparisons. A substance with RS more than 1 indicates that the estimated exposure is higher than e 279 
predicted no effect concentration, so more attention should be paid as the hazards might occur in the 280 
different environment compartments.  281 
The ranking results for parent compounds agree with some of the previous prioritisation studies. 282 
Amitriptyline, atorvastatin, carbamazepine, diclofenac, estradiol, mesalazine and orlistat were 283 
identified as priority substances in use in the Swedish market by Roos et al. [32], with the ranking at 284 
12
th
, 22
nd
, 16
th
, 5
th
, 4
th
, 10
th
 and 11
th
, respectively. The risk score of diclofenac [33] was also reported 285 
with a low RS value of 0.01 in a UK stream case study. Amoxicillin has been ranked the top in several 286 
veterinary medicine prioritisation studies, where it was classified as a substance with high hazard to 287 
aquatic environments in the UK [6, 7], Korea [34], US [35] and China [36]. Azithromycin and 288 
metformin were identified in a US surface water exercise, being ranked 12
th
 and 5
th
, respectively [35]. 289 
Clarithromycin has been identified in a prioritisation study in Germany and ranked 34
th
 [37]. 290 
Ciprofloxacin was classified as a substance  with a high ranking (8th) in the aquatic environment in 291 
US [35], besides, it was assigned to categories with a high and medium toxicity in China [36] and 292 
Korea [34], respectively. Omeprazole was considered in the prioritisation studies in the US and 293 
Sweden, ranking 18th and 22nd, respectively [32, 35].  294 
Previously published work considering the prioritisation of pharmaceuticals has only focused on 295 
parent compounds [8, 32], whereas in reality following consumption by patients, compounds may be 296 
metabolised and excreted as metabolites, partly or completely [6]. This project is the first study that 297 
considered the impact that metabolism may have on the ranking of APIs. The ranking results 298 
demonstrated that it is important to consider these compounds, particularly the metabolites of 299 
atorvastatin (ortho-hydroxyatorvastatin and para-hydroxyatorvastatin) which were highly ranked using 300 
a number of the prioritisation indices. The classification of ‘over-the-counter’ APIs is a novel method 301 
applied in a prioritisation exercise, and therefore, no published works are available with which to 302 
compare our findings. 303 
Potential risk of highly ranked substances in the environment  304 
A number of the compounds we identified as high priority are receiving increasing regulatory scrutiny. 305 
For example, as part of Directive 2013/39/EU) [38] which relates to priority substances in water, three 306 
APIs: diclofenac and two hormones 17-beta-estradiol (E2) and 17-alpha-ethinylestradiol (EE2) have 307 
been added to EU’s pollutant watch list, two of these (diclofenac and E2) appear in our top 16 list. 308 
While EE2 did not fall in the top 16, it was still ranked highly using the plasma therapeutic 309 
concentration approach (number 11), even though the amounts of this compound used in the UK are 310 
small. Side effects of diclofenac on the fish kidneys (histopathological damages) have been 311 
documented [39, 40]. Diclofenac is also considered to have threatened some sensitive organisms (e.g. 312 
vultures from the Gyps genus) through secondary poisoning [41]. E2 and EE2 are the two APIs for 313 
which the toxicity have been determined at environmental relevant concentrations. E2 is a natural 314 
estrogen with endocrine disrupting properties. Potent effects of E2 on gamete quality and maturation 315 
in two salmonid species (rainbow trout Oncorhynchus mykiss and grayling Thymallus thymallus) have 316 
been reported, even at ng/L exposure concentration levels [42]. 17-alpha-ethinylestradiol (EE2) has 317 
been ranked in the top 20 list (Table 3). There is widespread evidence that exposure of male fish to 318 
EE2 at ng/L levels can result in feminzation of male fish [43] and that chronic exposure of fish (i.e. 319 
fathead minnow Pimephales promelas) to EE2 could ultimately result in a the collapse of fathead 320 
minnow populations in surface waters [44].  321 
The watch list has been further developed in the European Environmental Quality Standards Directive 322 
[4], where four antibiotics including erythromycin, clarithromycin, azithromycin and ciprofloxacin have 323 
been added. The inclusion of antibiotics in the watch list is mainly due to their potential toxic effects to 324 
algal species. Three of these antibiotics (clarithromycin, azithromycin and ciprofloxacin) were 325 
identified as top priority in the current study. The 72/96 h acute EC50 values with growth as the 326 
endpoint for these free antibiotics are 0.002 mg/L
 
(Pseudokirchneriella subcapitata) [45], 0.001 ug/L 327 
(unreported blue-green algae) [24] and 0.005 mg/L (Microcystis aeruginosa) [46], respectively. 328 
The occurrence of some of the highly ranked parent APIs in aquatic the environment has been 329 
reported with concentrations at ng/L in surface waters and at up to µg/L levels in WWTP effluents [47]. 330 
Amitriptyline was reported to inhibit the growth of the macrophyte Lemna minor with 7 d EC50 1.69 331 
mg/L [48] and cause inhibition of crustacea Daphnia magna with an EC50 of 5 mg/L [49]. Atorvastatin 332 
and metformin were reported to inhibit the growth of a wide range of organisms such as macrophyte 333 
(e.g. lemna) and vertebrate (e.g. fish), where the lowest 14 d NOEC 0.013 ug/L of atorvastatin with 334 
genetic endpoint was documented for Zebrafish (Danio rerio) [25] and 48 h LC50 1.35  mg/L of 335 
metformin for a crustacea Daphnia magna [50]. While currently no experimental toxicity data were 336 
recorded for mesalazine and omeprazole, in the present study a read-cross approach was used to 337 
predict their hazards to aquatic organisms. The lowest predictive chronic toxicity data of mesalazine 338 
and omeprazole each was 0.031 mg/L and 0.009  mg/L, both of these being for crustacea Daphnia 339 
magna. Hazards of five classified OTC APIs to three aquatic trophic levels have been illustrated in 340 
Table 5. Of the three highly ranked metabolites, only the occurrence of 10,11-epoxycarbamazepine 341 
has been reported, with a mean value of 19.1 ng/L in the  WWTP effluent [47].  342 
Except for the impacts of prioritised APIs on organism and population levels of non-target organisms 343 
in the environment, side effects of some targeted APIs (Table 6) on the cellular and genomic levels 344 
have also been documented. Hepatocyte cytotoxicity of the antibiotic amoxicillin has been reported in 345 
rainbow trout (Oncorhynchus mykiss) with a 24 h EC50 >182.7 mg/L [51]. Detrimental effects of 346 
carbamazepine on the liver and kidney cytopathology of rainbow trout (Oncorhynchus mykiss) has 347 
been observed with LOECs >0.1 and 0.001 mg/L, respectively [52]. Carbamazepine and diclofenac 348 
have been reported to significantly affect the genomic template stability in Zebrafish, at concentrations 349 
of 310 ng/L and 810 ng/L, respectively [53]. Niemuth et al. [54] found that 4 wk metformin exposure at 350 
the concentration of 40 ng/L causes potential endocrine disruption in adult male fathead minnows 351 
(Pimephales promelas), through inducing significant up-regulation of messenger ribonucleic acid 352 
(mRNA) encoding the protein vitellogenin.    353 
In terrestrial environments, the antiepileptic carbamazepine and antiobesity orlistat were the two 354 
highest ranked substances. The occurrence of carbamazepine in soil was reported at concentrations 355 
up to 6.85 x 10
-3
 mg/kg, and the QSAR based 14 d LC50 toxicity to earthworm was 1060 mg/kg. 356 
While the detection of orlistat in the terrestrial environment has not been reported, a relatively high 357 
experimental BCF of 51.1 for the orlistat treated earthworm has been documented [55] and the 358 
predictive 14 d LC50 toxicity to earthworm was 28.28 mg/kg. It should be recognised that prioritisation 359 
of several substances was based on the predicted properties and/ or toxicity data (Table 6), especially 360 
for Koc values that were absent for all compounds. For some prioritised substances selected from 361 
subtle pharmacological effect scenario, exposures (FssPC) were all estimated from log Kow on the 362 
basis of QSAR.  363 
Limitation of methods and future improvement 364 
Approaches for exposure estimations of APIs used in the present study rely heavily on the annual 365 
usage information for individual pharmaceutical active ingredients. However it is well recognised that 366 
as well as the primary and secondary care pharmaceutical usage, for a limited number of compounds 367 
‘over-the-counter’ sales through retail outlets such as supermarkets and pharmacies may add a 368 
significant contribution to the overall usage [56]. Attempts were made to obtain quantitative usage 369 
data for OTC compounds during the present study but these were unsuccessful. A previous study has 370 
estimated that in Germany OTC usage can contribute up to 50% of the total usage of some 371 
pharmaceuticals. However, this can vary on a compound by compound basis, and usage through this 372 
route could not be included in the quantitative risk score based element of this project. An accurate 373 
quantification approach of OTC usage should be further established. 374 
The exposure of APIs in the terrestrial environment was estimated by only considering a simple input 375 
pathway: APIs adsorbed to sludge in WWTP and a this sludge was then applied to the land [18]. 376 
Experimentally determined biodegradation data of APIs were not available. PECs and therefore, the 377 
risk scores of APIs that were susceptible to biodegradation during wastewater treatment will therefore 378 
have been significantly overestimated. Limited information on experimental physical-chemical 379 
properties such as soil-water partition coefficients (Koc) was available for some listed APIs. To fill in 380 
the data gaps, an empirical estimation model developed by Franco and Trapp [20] was used to 381 
estimate adsorption during wastewater treatment. This model was developed for soils and its 382 
applicability to estimating sorption in sludge is not known. The model also omits selected sorption 383 
processes, such as complexation, which may be important for some pharmaceuticals [20]. 384 
In the secondary poisoning assessment of APIs in the terrestrial compartment, as very limited 385 
experimental data was available on bioconcentration factors for worms (BCFworm), this parameter was 386 
predicted using the regression equation outlined in TGD [17]. This regression can well describe 387 
uptake by worms kept in water. However, evaulation of the model against real data indicate that the 388 
estimated BCFworm in the soil are usually higher than the experimental BCFs [17]. Higher PECoral, 389 
predator(earthworm) values than those that occur in reality could therefore have been obtained in the current 390 
study, and secondary poisoning effects of APIs in terrestrial environments on earthworm-eating birds 391 
may well be overestimated. Therefore, an improvement in the accuracy of BCFworm estimation in soil 392 
warrants further consideration. 393 
To target the metabolites for prioritisation, metabolic rates and metabolites of a wide range of APIs in 394 
human have been identified from the literature (e.g. Drugbank [19]). However for substances without 395 
metabolism information, we assumed that no biodegradation and biotransformation occurred in the 396 
body to implement a conservative risk score estimation [34]. In this case, the exposures of these 397 
parent compounds in aquatic and terrestrial compartments may have been overestimated, and their 398 
metabolites will have been missed in our prioritisation list. For the highly ranked compounds without 399 
available metabolism data, it is recommended that information on the properties such as the excretion 400 
rate of parent compounds and the properties and toxicities of related metabolites should be produced. 401 
Conclusions 402 
A holistic methodology has been developed and implemented to prioritise pharmaceuticals of concern 403 
that are released into the environment through wastewater. Pharmaceutical usage data in the UK has 404 
been used, together with information on the physical-chemical properties, patient metabolism and 405 
wastewater treatment removal to estimate concentrations in the aquatic and terrestrial environments.  406 
To rank the APIs, these concentrations have been compared to a range of hazard end-points. A 407 
series of end-points have been considered, including traditional risk assessment PEC/PNEC ratios for 408 
the aquatic and terrestrial compartments as well as non-standard endpoints such as the potential for 409 
subtle pharmacological effects and the impact on animals consuming fish and earthworms.   410 
Sixteen substances, including parent compounds from the therapeutic classes of antibiotic, 411 
antidiabetic, anti-inflammatory, antidepressant, antiobesity, antisecretory, lipid modifying agents, 412 
antiepileptics, estrogens and three metabolites have been highly ranked. Due to significant data gaps, 413 
the rankings of some compounds were based on data generated from predictive methods. A targeted 414 
monitoring study for these compounds, therefore, needs to be performed at a few treatment works to 415 
identify whether or not these high priority substances do occur in wastewater effluents and sludge.  416 
While, the approach has been illustrated for the UK, there is no reason why the concept cannot be 417 
applied to identify APIs of priority in other regions of the World. In doing this, the risk ranking 418 
algorithms may need to be refined to reflect regionally relevant pathways of exposure. We believe that 419 
the broader application of the approach would be highly beneficial in focusing monitoring and testing 420 
on substances that really matter which should ultimately result in better protection of the natural 421 
environment and of human health. 422 
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 578 
579 
Table 1 Classification categories for chemicals without adequate available chronic aquatic toxicity 580 
data 581 
Category Concentration range (mg/L) 
Chronic 1 <=1 
Chronic 2 >1 to <=10 
Chronic 3 >10 to <=100 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
 596 
Table 2 Summary of the numbers of compounds selected for prioritisation from each compound 597 
identification method and availability of experimental ecotoxicological data collated for the 146 598 
compounds under consideration 599 
Prioritisation 
type 
Compound 
identification 
methodology 
Number of 
compounds 
Parameter Number of 
compounds 
Quantitative 
prioritisation 
Primary care usage 
a 
88
a 
Acute Fish LC50 89 
 
Secondary care 
usage 
a 
20
a 
 Daphnia EC50 76 
 High hazard concern 12  Algae EC50 74 
 Metabolites 25   
 CIP1 4 Chronic Fish LC50 13 
 TOTAL 146  Daphnia EC50 40 
Qualitative 
prioritisation 
Over-the-counter 23 
  
   
Bioconcentration factor in 
fish 
3 
   
Therapeutic plasma 
concentration 
113 
   Acceptable daily intake 139 
   Mammalian toxicity 65 
a
 – three compounds, paracetamol, codeine and amoxicillin, identified as high usage in primary and secondary care 600 
 601 
 602 
 603 
 604 
 605 
Table 3 Top 20 compounds from each prioritisation approach for exposure via water. 606 
Risk Score 
Low trophic levels 
Higher trophic levels 
FssPC: HtPC ratio 
Mammalian predator Human (uptake from drinking water) 
Acute aquatic 
(PECsw/ acute 
PNECaquatic) 
Chronic aquatic 
(PECsw/ chronic 
PNECaquatic) 
PECfish: PNECmammal PECfish: ADI Adult 
(PECsw: PNECadult) 
Child 
(PECsw: PNECchild) 
>10 1 amoxicillin 
 
 
1 diclofenac 
 
n.d. n.d. n.d. n.d. 
1 ortho-hydroxy 
   atorvastatin 
2 para-hydroxy 
   Atorvastatin 
1 – 10 2 clarithromycin 
3 ciprofloxacin 
4 azithromycin 
5 metformin 
6 mesalazine 
2 atorvastatin 
3 estradiol 
4 mesalazine 
5 omeprazole 
 
n.d. n.d. n.d. n.d. 
3 atorvastatin 
4 estradiol 
5 amitriptyline 
 
0.1 – 1 7 paracetamol 
8 phenytoin 
9 n-acetyl-5- 
   aminosalicylic acid 
10 omeprazole 
11 iminoquinone 
12 mycophenolic 
acid 
13 norsertraline 
14 sulfasalazine 
15 ranitidine 
16 oxytetracycline 
17 homovanillic acid 
18 carbocisteine 
19 mebeverine 
20 propanolol 
6 paracetamol 
7 mebeverine 
8 sulfasalazine 
 
1 diazepam 
 
n.d.  n.d. n.d. 
6 tamoxifen 
7 propranolol 
8 norsertraline 
9 terbinafine 
<0.1 
n.d. 
9 codeine 
10 fluoxetine 
11 azithromycin 
12 diltiazem 
13 mefenamic 
acid 
14 ranitidine 
15 clarithromycin 
16 terbinafine 
17 metformin 
18 etodolac 
19 carbocisteine 
20 atenolol 
2 miconazole 
3 paracetamol 
4 propanolol 
5 tramadol 
6 naproxen 
7 quinine 
8 trazodone 
9 diltiazem 
10 ibuprofen 
11 ranitidine 
12 
cyclophosphamide 
13 carbamazepine-o-
quinone 
1 miconazole 
2 phenytoin 
3 ortho-
hydroxyatorvastatin 
4 estradiol 
5 para-
hydroxyatorvastatin 
6 simvastatin 
7 omeprazole sulfone  
8 2-oxoclopidogrel 
9 omeprazole 
10 propanolol 
11 diltiazem 
12 norsertraline 
1 phenytoin 
2 metformin 
3 simvastatin 
4 estradiol 
5 codeine  
6 omeprazole sulfone 
7 lisinopril 
8 paracetamol 
9 para-hydroxy 
   atorvastatin 
10 citalopram 
11 ortho-hydroxy 
     atorvastatin 
12 5’-o-desmethyl 
1 phenytoin 
2 metformin 
3 simvastatin 
4 estradiol 
5 codeine  
6 omeprazole 
sulfoned 
7 lisinopril 
8 paracetamol 
9 para-hydroxy 
   atorvastatin 
10 citalopram 
11 ortho-hydroxy 
     atorvastatin 
10 simvastatin 
11 
ethinylestradiol 
12 amlodipine 
13 diltiazem 
14 fenofibrate 
15 quetiapine 
16 miconazole 
17 ibuprofen 
18 azithromycin 
19 tramadol 
20 donepezil 
 
14 iminoquinone 
15 phenytoin 
16 2-oxoclopidogrel 
17 lidocaine 
18 2-
hydroxyiminostilbene 
19 mycophenolic 
acid 
20 carbamazepine 
diol 
13 tramadol 
14 irbesartan 
15 terbinafine 
16 quetiapine 
17 tamoxifen 
18 citalopram 
19 5'-o-desmethyl 
omeprazole 
20 codeine 
     omeprazole 
13 naproxen 
14 gliclazide 
15 3-hydroxy 
     omeprazole 
16 5-hydroxy 
     omeprazole 
17 2-oxoclopidogrel 
18 omeprazole 
19 pancreatin 
20 diltiazem 
12 5’-o-desmethyl 
     omeprazole 
13 naproxen 
14 gliclazide 
15 3-hydroxy 
     omeprazole 
16 5-hydroxy 
     omeprazole 
17 2-oxoclopidogrel 
18 omeprazole 
19 pancreatin 
20 diltiazem 
n.d. no data 607 
 608 
 609 
 610 
 611 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
Table 4 Top 20 compounds from each prioritisation approach considered, according to the predicted 625 
concentrations in soil (PECsoil) 626 
Risk score 
Low trophic levels 
Higher trophic levels 
Mammalian predator 
PECsoil: PNECearthworm 
PECearthworm : PNECmammal PECearthworm : ADI 
>10 n.d. n.d. n.d. 
1 – 10 
1 orlistat 
2 10,11-epoxycarbamazepine 
3 carbamazepine 
n.d. n.d. 
0.1 – 1 
4 venlafaxine 
5 dipyridamole 
6 progesterone 
7 3-hydroxyquinine 
8 2-hydroxyiminostilbene 
9 norsertraline 
10 terbinafine 
n.d. 1 orlistat 
<0.1 
11 cyproterone 
12 norerythromycin 
13 3-hydroxycarbamazepine 
14 2-hydroxycarbamazepine 
15 metoprolol 
16 atorvastatin 
17 levetiracetam 
18 methocarbamol 
19 bisoprolol 
20 amitriptyline 
1 phenytoin 
2 bisoprolol 
3 progesterone 
4 3-hydroxyquinine 
5 diazepam 
6 10,11-epoxycarbamazepine 
7 carbamazepine 
8 quinine 
9 normorphine 
10 fluoxetine 
11 isosorbide 
12 amitriptyline 
13 miconazole 
14 ranitidine 
15 dipyridamole 
16 3-hydroxyomeprazole 
17 5-hydroxyomeprazole 
18 5'-O-desmethyl 
omeprazole 
19 2-hydroxyiminostilbene 
20 ibuprofen 
2 atorvastatin 
3 ortho-hydroxyatorvastatin 
4 tamoxifen 
5 estradiol 
5 terbinafine 
6 para-hydroxyatorvastatin 
7 bisoprolol 
8 phenytoin 
9 norsertraline 
10 10,11-epoxycarbamazepine 
11 dipyridamole 
12 fenofibrate 
13 venlafaxine 
14 miconazole 
15 carbamazepine 
16 isosorbide 
17 progesterone 
18 aripiprazole 
19 3-hydroxyomeprazole 
20 5-hydroxyomeprazole 
n.d. no data 627 
 628 
 629 
Table 5 Classification of over the counter pharmaceuticals based on potential hazard to the aquatic 630 
environment 631 
Pharmaceutical 
Acute aquatic ecotoxicity  
(mg/L) 
Chronic ecotoxicity 
(mg/L) 
Classification 
category 
 Algae Daphnia Fish Daphnia Fish  
Acrivastine n.a. n.a. n.a. n.a. n.a. Not classified 
Amorolfine 0.69
a
 0.68
 a
 >500
b
 n.a. n.a. Chronic 1 
Beclometasone dipropionate n.a. n.a. 23.7
 a
 n.a. n.a. Chronic 3 
Benzalkonium chloride 0.056
b
 0.037
b
 0.28
b
 0.04
 b
 0.032
 b
 Chronic 1 
Cetirizine hydrochloride 102
 a
 29.6
 a
 n.a. 15.2
 a
 n.a. Chronic 3 
Cetrimide 1.03
 a
 1.38
 a
 4.63
 a
 n.a. n.a. Chronic 2 
Cetylpyridinium chloride 1.26
 a
 0.0032
b
 0.11
b
 0.44
 a
 n.a. Chronic 1 
Chlorphenamine maleate 5.05
 a
 n.a n.a n.a n.a Chronic 2 
Clotrimazole n.a. n.a. 30
b
 n.a. n.a. Chronic 3 
Dexpanthenol n.a. 76.5
 a
 1220
 a
 n.a. n.a. Chronic 3 
Dextromethorphan  2.6
 a
 0.95
 a
 5.81
 a
 2.04
 a
 n.a. Chronic 1 
Dimethicone n.a. 0.36
 a
 5.83
 a
 0.096
 a
 n.a. Chronic 1 
Fluticasone propionate n.a. n.a. 39.4
 a
 n.a. n.a. Chronic 3 
Guaifenesin 9.26
 a
 292
 a
 n.a. 6.08
 a
 n.a. Chronic 2 
Hexylresorcinol 2.19
 a
 11.7
 a
 2.89
 a
 3.6
 a
 n.a. Chronic 2 
Loperamide hydrochloride >54
c
 >56
c
 >52.3
c
 n.a n.a Chronic 3 
Loratadine 0.7
c
 0.83
c
 0.38
c
 n.a n.a Chronic 1 
Mepyramine maleate 8.12
 a
 181
 a
 20.4
 a
 10.7
 a
 n.a Chronic 2 
Phenylephrine 78.1
 a
 40.8
 a
 210
 a
 8.19
 a
 n.a Chronic 2 
Pholcodine 83.4
 a
 401
 a
 855
 a
 54.2
 a
 n.a Chronic 3 
Pseudoephedrine 15.7
 a
 95.7
 a
 331
 a
 7.23
 a
 n.a Chronic 2. 
Sodium cromoglicate n.a n.a n.a n.a n.a Not classified 
Xylometazoline hydrochloride 2.17
 a
 n.a 0.66
 a
 0.49
 a
 n.a Chronic 1 
a
 estimated by QSAR toolbox; 
b
 EPA ecotox; 
c
 FASS; 
d 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
 644 
 645 
 646 
 647 
 648 
Table 6 Data gaps for the highly ranked substances 649 
Compound Priority scheme Comments 
Amitriptyline, Subtle pharmacological effect Predicted FssPC 
Amoxicillin, Acute aquatic low trophic level Predicted Koc, 
Atorvastatin, Chronic aquatic low trophic level Predicted Koc 
 Subtle pharmacological effect Predicted FssPC 
Azithromycin, Acute aquatic low trophic level Predicted Koc 
Carbamazepine, Terrestrial low trophic level Predicted Koc, LC50 earthworm 
Ciprofloxacin, Acute aquatic low trophic level Predicted Koc 
Clarithromycin, Acute aquatic low trophic level Predicted Koc 
Diclofenac, Chronic aquatic low trophic level Predicted Koc, 
Estradiol Subtle pharmacological effect Predicted FssPC 
Metformin, Acute aquatic low trophic level Predicted Koc, 
Mesalazine Acute aquatic low trophic level Predicted Koc, acute daphnia LC50 
 Chronic aquatic low trophic level Predicted Koc, chronic daphnia NOEC 
Omeprazole, Chronic aquatic low trophic level Predicted Koc, chronic daphnia NOEC 
Orlistat Terrestrial low trophic level Predicted Koc, LC50 earthworm 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
661 
  (A) 662 
 (B) 663 
Figure 1: The overall approach for prioritisation of activated pharmaceutical ingredients (APIs). Risk 664 
scores on (A) standard end-point effect; (B) non-standard end-point effects. Green: estimated 665 
exposure; Orange: estimated effect. PNECaquatic: predicted no effect concentration for aquatic 666 
organisms, including fish, daphnia and algae; PECsw: predicted environmental concentration in 667 
surface water; PECsoil: predicted environmental concentration in soil; PNECearthworm: predicted no effect 668 
concentration in earthworm; FssPC: fish steady state plasma concentration; HtPC: human therapeutic 669 
plasma concentration; PECearthworm: predicted environmental concentration in earthworm; PECfish:  670 
predicted environmental concentration in fish; ADI: acceptable daily intake for human; PNECmammal: 671 
predicted no effect concentration in mammal; PNECadult: predicted no effect concentration for adult; 672 
PNECchild: predicted no effect concentration for child.  673 
 674 
 675 
